Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.51
(-0.79%)
HKD 2.51
(-0.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 518.12 Million CNY | -28.34% |
| 2022 | 722.98 Million CNY | 22.21% |
| 2021 | 591.58 Million CNY | 20.19% |
| 2020 | 492.21 Million CNY | -22.08% |
| 2019 | 631.67 Million CNY | 35.53% |
| 2018 | 466.07 Million CNY | 84.47% |
| 2017 | 252.65 Million CNY | 2.0% |
| 2016 | 247.69 Million CNY | -2.64% |
| 2015 | 254.42 Million CNY | 71.84% |
| 2014 | 148.06 Million CNY | -19.22% |
| 2013 | 183.29 Million CNY | -33.87% |
| 2012 | 277.18 Million CNY | 75.64% |
| 2011 | 157.81 Million CNY | 16.51% |
| 2010 | 135.44 Million CNY | 3.82% |
| 2009 | 130.46 Million CNY | 58.0% |
| 2008 | 82.56 Million CNY | 39.15% |
| 2007 | 59.33 Million CNY | 36.97% |
| 2006 | 43.32 Million CNY | 125.88% |
| 2005 | 19.17 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 464.49 Million CNY | -10.35% |
| 2024 Q2 | 491.27 Million CNY | 5.77% |
| 2023 FY | 518.12 Million CNY | -28.34% |
| 2023 Q2 | 716.03 Million CNY | 21.7% |
| 2023 Q1 | 588.37 Million CNY | -18.62% |
| 2023 Q3 | 609.24 Million CNY | -14.92% |
| 2023 Q4 | 518.12 Million CNY | -14.96% |
| 2022 Q4 | 722.98 Million CNY | 3.93% |
| 2022 FY | 722.98 Million CNY | 22.21% |
| 2022 Q3 | 695.63 Million CNY | 20.08% |
| 2022 Q2 | 579.3 Million CNY | 10.89% |
| 2022 Q1 | 522.41 Million CNY | -11.69% |
| 2021 Q3 | 478.4 Million CNY | 5.39% |
| 2021 Q2 | 453.91 Million CNY | 14.37% |
| 2021 FY | 591.58 Million CNY | 20.19% |
| 2021 Q1 | 396.86 Million CNY | -19.37% |
| 2021 Q4 | 591.58 Million CNY | 23.66% |
| 2020 Q1 | 617.12 Million CNY | -2.3% |
| 2020 Q2 | 533.84 Million CNY | -13.49% |
| 2020 Q3 | 492.18 Million CNY | -7.8% |
| 2020 Q4 | 492.21 Million CNY | 0.0% |
| 2020 FY | 492.21 Million CNY | -22.08% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | 509.34 Million CNY | 0.0% |
| 2019 Q4 | 631.67 Million CNY | 0.0% |
| 2019 FY | 631.67 Million CNY | 35.53% |
| 2018 Q1 | 318.94 Million CNY | 26.24% |
| 2018 Q4 | 466.07 Million CNY | 3.67% |
| 2018 Q3 | 449.56 Million CNY | 35.78% |
| 2018 FY | 466.07 Million CNY | 84.47% |
| 2018 Q2 | 331.1 Million CNY | 3.81% |
| 2017 FY | 252.65 Million CNY | 2.0% |
| 2017 Q3 | 239.32 Million CNY | -23.49% |
| 2017 Q2 | 312.8 Million CNY | 5.13% |
| 2017 Q1 | 297.53 Million CNY | 20.12% |
| 2017 Q4 | 252.65 Million CNY | 5.57% |
| 2016 Q2 | 230.31 Million CNY | 8.41% |
| 2016 Q4 | 247.69 Million CNY | 6.95% |
| 2016 FY | 247.69 Million CNY | -2.64% |
| 2016 Q1 | 212.43 Million CNY | -16.5% |
| 2016 Q3 | 231.6 Million CNY | 0.56% |
| 2015 Q3 | 235.04 Million CNY | -28.48% |
| 2015 FY | 254.42 Million CNY | 71.84% |
| 2015 Q2 | 328.64 Million CNY | 9.17% |
| 2015 Q4 | 254.42 Million CNY | 8.24% |
| 2015 Q1 | 301.05 Million CNY | 103.33% |
| 2014 FY | 148.06 Million CNY | -19.22% |
| 2014 Q4 | 148.06 Million CNY | 22.26% |
| 2014 Q3 | 121.1 Million CNY | -17.82% |
| 2014 Q2 | 147.37 Million CNY | 27.35% |
| 2014 Q1 | 115.72 Million CNY | -36.86% |
| 2013 Q2 | 189.45 Million CNY | 0.0% |
| 2013 Q4 | 183.29 Million CNY | 0.0% |
| 2013 FY | 183.29 Million CNY | -33.87% |
| 2013 Q1 | - CNY | -100.0% |
| 2012 Q2 | 209.55 Million CNY | 0.0% |
| 2012 FY | 277.18 Million CNY | 75.64% |
| 2012 Q4 | 277.18 Million CNY | 0.0% |
| 2011 FY | 157.81 Million CNY | 16.51% |
| 2011 Q2 | 168.8 Million CNY | 0.0% |
| 2011 Q4 | 157.81 Million CNY | 0.0% |
| 2010 Q2 | 151.23 Million CNY | 0.0% |
| 2010 FY | 135.44 Million CNY | 3.82% |
| 2010 Q4 | 135.44 Million CNY | 0.0% |
| 2009 FY | 130.46 Million CNY | 58.0% |
| 2008 FY | 82.56 Million CNY | 39.15% |
| 2007 FY | 59.33 Million CNY | 36.97% |
| 2006 FY | 43.32 Million CNY | 125.88% |
| 2005 FY | 19.17 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -264.153% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 92.848% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -204.051% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | 26.989% |
| Qianhai Health Holdings Limited | 94 Million HKD | -451.178% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 44.292% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 42.672% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | 22.132% |
| PuraPharm Corporation Limited | 689.65 Million HKD | 24.872% |
| SSY Group Limited | 4.49 Billion HKD | 88.471% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -41.273% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 52.487% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.692% |